Cancer Metabolism Company Metabomed Raises $12.5 Million
The company develops cancer-fighting drugs that specifically target the reprogrammed cancer cells’ metabolism to halt their growth
Adi Pick | 15:51 19.12.2019
Yavne, Israel-based cancer metabolism company Metabomed Ltd. has raised a $12.5 million funding round, the company announced Thursday. The round was led by Yonjin Venture, with participation from existing investors M Ventures, Pfizer Ventures, Pontifax Venture Fund, Boehringer Ingelheim Venture Fund, and Arkin Bio Ventures. The company intends to use the funds to accelerate its drug towards clinical trials.